secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0000950170-25-112570
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics presents new aficamten data at ESC 2025; shows improvement vs metoprolol
--------------------------------------------------------------------------------

- MAPLE-HCM: aficamten superior to metoprolol on diastolic function, SAM, and LVOT obstruction (p<0.001); reduced max wall thickness (-1.01mm, p=0.015).
- Atrial fibrillation annual incidence with aficamten was 1.5%, consistent with predicted HCM-AF and CHARGE-AF rates; minimal clinical impact.
- Integrated safety of 463 patients (~700 patient-years) shows similar AE profile to placebo; low LVEF<50% incidence, no permanent discontinuations.
- Longer-term FOREST-HCM: 69% and 93% of patients improved NYHA class at Week 12 and 96; KCCQ-CSS +15 and +16.
- FDA NDA under review with PDUFA target action date of December 26, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025112570/0000950170-25-112570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025112570/cytk-20250831.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-112570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer